查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1446526

重组蛋白治疗 CDMO 市场规模、份额、趋势分析报告：按类型、来源、适应症、地区、细分市场预测，2024-2030 年

Recombinant Protein Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents, Others), By Source, By Indication, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 173 Pages | 商品交期: 2-10个工作天内

价格

重组蛋白治疗 CDMO 市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球重组蛋白治疗CDMO市场将达到520亿美元，2024年至2030年复合年增长率为13.95%。

新型重组蛋白疗法开发方面不断涌现的技术创新以及生技药品研发的不断增加预计将对重组蛋白治疗 CDMO 产业产生积极影响。由于各种技术创新，新型重组蛋白疗法的开发取得了重大进展。

重组蛋白是将编码所需蛋白的基因引入宿主细胞（通常是微生物或哺乳动物细胞）以表达和生产所需蛋白而产生的生物技术蛋白。目前正在采用多种蛋白质工程平台技术来瞄准精度和功能，并提高新型蛋白质疗法的循环半衰期。这些技术还旨在提高产量并确保产品纯度。

此外，随着越来越多的公司投资于含有重组蛋白的生技药品的研发，生物製药产业正在经历显着成长。这种增长是由製造技术的进步所推动的，包括采用一次性反应器和其他创新製造方法。例如，2024 年 1 月，Eurofins CDMO Alphora, Inc. 宣布完成了一个中试规模的生技药品开发设施。该设施占地 3,300 平方英尺，致力于单株抗体 (mAb) 和其他哺乳动物来源的治疗性蛋白质的开发和规模化生产。

此外，全球自体免疫、自体免疫疾病和代谢性疾病等慢性和复杂疾病的盛行率不断上升，增加了对创新和有效治疗方案的需求。重组蛋白疗法提供了多种候选药物来解决这些复杂的疾病状态。例如，美国癌症协会估计，2023 年美国将新增约 1,958,310 例癌症病例，并有 609,820 例癌症相关死亡。此外，根据牛津大学发表的研究论文，到2022年6月核准并上市的抗体疗法数量将达到162种，其中约一半（42.6%）是为癌症治疗而开发的。

2023年3月，美国FDA加速核准Incyte公司的retifanlimab-dlwr用于治疗转移性或復发性局部晚期默克尔细胞癌（MCC）成年患者。癌症的生物疗法也支持修復、刺激和增强免疫反应。因此，许多製药和生物製药公司都渴望投资新的癌症相关治疗方法。总的来说，这些进步旨在生产越来越多的高品质产品。

重组蛋白治疗 CDMO 市场报告亮点

  • 2023年，其他细分市场将主导市场。该领域的成长是由重组蛋白疗法的兴起所推动的，重组蛋白疗法是比血浆衍生产品更安全的选择，因为它们具有减少感染疾病源性传播的潜力。
  • 从供应来源来看，哺乳动物系统占最大市场占有率，2023年将达67.4%。这是由于越来越多地采用哺乳动物系统作为重组蛋白的来源。哺乳动物细胞培养系统有利于生产具有适当转译后修饰的复杂蛋白质，使其适用于广泛的治疗应用。
  • 有迹象表明，到2023年，代谢疾病细分市场将占21.8%的市场占有率。该行业受到人口老化和製药行业强劲需求的推动，从而促进了该行业的崛起。
  • 2023 年，北美市场占据主导地位，份额为 38.5%。该地区拥有强大的研发基础设施和强劲的生物製药产业，有助于市场成长。此外，美国拥有高度发展的生物製药生产基础设施，包括重组蛋白疗法。

目录

第一章调查方法与范围

第 2 章 第 2 章执行摘要

  • 市场概述
  • 分段简介
  • 竞争形势概览

第 3 章 重组蛋白治疗 CDMO 市场：变数、趋势、范围

  • 市场体系展望
  • 重组蛋白治疗 CDMO 市场动态
  • 重组蛋白治疗 CDMO 市场：分析工具
  • COVID-19 对重组蛋白治疗 CDMO 市场的影响
  • COVID-19 对生物加工和外包的影响

第 4 章 重组蛋白治疗 CDMO 市场：类型估计与趋势分析

  • 定义和范围
  • 细分仪表板
  • 全球重组蛋白治疗CDMO市场波动分析
  • 2018-2030 年全球重组蛋白治疗 CDMO 市场规模及趋势分析（按类型）

第五章重组蛋白治疗 CDMO 市场：来源估计与趋势分析

  • 定义和范围
  • 细分仪表板
  • 全球重组蛋白治疗CDMO市场波动分析
  • 2018-2030 年全球重组蛋白治疗 CDMO 市场规模及趋势分析（依来源）

第六章重组蛋白治疗CDMO市场：适应症估计与趋势分析

  • 定义和范围
  • 细分仪表板
  • 全球重组蛋白治疗CDMO市场波动分析
  • 2018-2030年全球重组蛋白治疗CDMO市场规模及趋势分析（依适应症）

第 7 章 重组蛋白治疗 CDMO 市场：按类型、来源和适应症分類的区域估计和趋势分析

  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模及预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争形势

  • 公司分类
  • 2023 年重组蛋白治疗 CDMO市场占有率分析
  • Major Deals and Strategic Alliances Analysis
    • 策略规划
    • 扩张
    • 合伙
    • 获得
  • 供应商形势
    • Key company market share analysis, 2023
    • Richter-Helm BioLogics
    • Lonza
    • Catalent, Inc
    • FUJIFILM Diosynth Biotechnologies
    • WuXi Biologics
    • Curia Global, Inc.
    • Batavia Biosciences BV
    • HALIX BV
    • BIOVIAN
    • Enzene Biosciences Ltd
Product Code: GVR-4-68040-116-2

Recombinant Protein Therapeutics CDMO Market Growth & Trends:

The global recombinant protein therapeutics CDMO market is expected to reach USD 52.0 billion by 2030 and is expected to expand at a CAGR of 13.95% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing technological innovations about the development of novel recombinant protein therapeutics and rising research and development for biologics are anticipated to influence the recombinant protein therapeutics CDMO industry positively. The development of novel recombinant protein therapeutics has observed significant advancements due to various technological innovations.

Recombinant proteins are bioengineered proteins produced by introducing the gene encoding the desired protein into a host cell, typically a microorganism or a mammalian cell, to express and produce the protein of interest. Several protein engineering platform technologies are currently employed to enhance the circulating half-life, targeting the precision and functionality of novel therapeutic protein drugs. These technologies also aim to boost production yield and ensure product purity.

Besides, the biopharmaceutical industry has witnessed significant growth, with an increasing number of companies investing in research and development of biologics, including recombinant proteins. This growth has been facilitated by advancements in manufacturing technologies, including adopting single-use bioreactors and other innovative production methods. For instance, in January 2024, Eurofins CDMO Alphora, Inc. announced the successful completion of its pilot-scale biologics development facility. With an expansive area of 3,300 square feet, this facility is exclusively dedicated to developing and scaling monoclonal antibodies (mAbs) and other therapeutic proteins derived from mammalian sources.

Moreover, the global increase in the prevalence of chronic and complex diseases, such as cancer, autoimmune disorders, & metabolic diseases, has increased the demand for innovative and effective therapeutic options. Recombinant protein therapeutics offer a diverse range of candidates to address these complex medical conditions. For instance, based on estimates from the American Cancer Society, it is projected that in 2023, there will be approximately 1,958,310 new cases of cancer and 609,820 cancer-related deaths in the U.S. Furthermore, according to a research article published by Oxford University, in June 2022, the number of approved and marketed antibody therapies reached 162, nearly half of which (42.6%) were being developed for the treatment of cancer.

In March 2023, the U.S. FDA granted accelerated clearance to Incyte Corporation's retifanlimab-dlwr for the treatment of adult patients with metastatic or recurrent, locally advanced Merkel Cell Carcinoma (MCC). Besides, biological therapy in cancer supports repairing, stimulating, or enhancing the immune response. Therefore, many pharmaceutical & biopharmaceutical companies are willing to invest in cancer-related novel treatments.Such advancements collectively aim to achieve a higher yield of quality products.

Recombinant Protein Therapeutics CDMO Market Report Highlights:

  • The others segment dominated the market in 2023. The segment growth is driven by increasing recombinant protein therapies as a safer option than plasma-derived products owing to the potential to reduce bloodborne transmission of infectious diseases
  • Based on the source, mammalian systems held the largest market share of 67.4% in 2023 attributed to an increase in the adoption of mammalian systems for sourcing recombinant proteins. Mammalian cell culture systems offer advantages in producing complex proteins with appropriate post-translational modifications, making them suitable for a wide range of therapeutic applications
  • Based on indication, the metabolic disorders segment held a market share of 21.8% in 2023. The segment is driven by a growing aging population, and robust demand for pharmaceutical industry, which has contributed to its prominence in this field
  • North America dominated the market with a share of 38.5% in 2023. The region has a strong R&D infrastructure and a robust biopharmaceutical industry, which has contributed to the market growth. Furthermore, the U.S. has a sophisticated and well-developed manufacturing infrastructure for biopharmaceuticals, including recombinant protein therapeutics

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's InternalL Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
    • 1.3.5. Details Of Primary Research
  • 1.4. Information Or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. Market Definitions
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective - 1
    • 1.10.2. Objective - 2
    • 1.10.3. Objective - 3
    • 1.10.4. Objective - 4

Chapter 2. Chapter 2 Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Recombinant Protein Therapeutics CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Recombinant Protein Therapeutics CDMO Market Dynamics
    • 3.2.1. Market Driver Impact Analysis
      • 3.2.1.1. Rising Adoption Of Biologics And Biosimilars
      • 3.2.1.2. Technological Innovations About The Development Of Novel Recombinant Protein Therapeutics
      • 3.2.1.3. Increasing Rate Of Clinical Research To Boost Demand For Recombinant Protein Therapeutics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory Hurdles
      • 3.2.2.2. Challenges Related To Quality Control
  • 3.3. Recombinant Protein Therapeutics CDMO Market: Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
  • 3.4. Impact Of Covid-19 On Recombinant Protein Therapeutics CDMO Market
  • 3.5. Covid-19 Impact On Bioprocessing And Outsourcing
    • 3.5.1. Clinical Trial Supply & Logistics Services: Impact Of Covid-19
    • 3.5.2. Supply Chain
    • 3.5.3. Activities By CDMOs Increased Post-Covid-19 Pandemic, Supporting The Development Of Recombinant Protein Therapeutics
    • 3.5.4. Changes In The Long Term

Chapter 4. Recombinant Protein Therapeutics CDMO Market: Type Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Growth Hormones
    • 4.1.2. Interferons
    • 4.1.3. Vaccines
    • 4.1.4. Immunostimulating Agents
    • 4.1.5. Others
  • 4.2. Segment Dashboard
  • 4.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
  • 4.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
    • 4.4.1. Growth Hormones
      • 4.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.2. Interferons
      • 4.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.3. Vaccines
      • 4.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.4. Immunostimulating Agents
      • 4.4.4.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 5. Recombinant Protein Therapeutics CDMO Market: Source Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Mammalian Systems
    • 5.1.2. Microbial Systems
    • 5.1.3. Others
  • 5.2. Segment Dashboard
  • 5.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
  • 5.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Source, 2018 to 2030 (USD Million)
    • 5.4.1. Mammalian Systems
      • 5.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 5.4.2. Microbial Systems
      • 5.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 5.4.3. Others
      • 5.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 6. Recombinant Protein Therapeutics CDMO Market: Indication Estimates & Trend Analysis

  • 6.1. Definitions and Scope
    • 6.1.1. Oncology
    • 6.1.2. Infectious Diseases
    • 6.1.3. Immunological Disorders
    • 6.1.4. Metabolic Disorders
    • 6.1.5. Haematological Disorders
    • 6.1.6. Others
  • 6.2. Segment Dashboard
  • 6.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
  • 6.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
    • 6.4.1. Oncology
      • 6.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.2. Infectious Diseases
      • 6.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.3. Immunological Disorders
      • 6.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.4. Metabolic Disorders
      • 6.4.4.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.5. Haematological Disorders
      • 6.4.5.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 7. Recombinant Protein Therapeutics CDMO Market: Regional Estimates & Trend Analysis by Type, Source, Indication

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Scenario
      • 7.4.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Scenario
      • 7.4.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Scenario
      • 7.5.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Scenario
      • 7.5.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Scenario
      • 7.5.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Scenario
      • 7.5.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Scenario
      • 7.5.6.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Scenario
      • 7.5.7.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Scenario
      • 7.5.8.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Scenario
      • 7.5.9.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Scenario
      • 7.6.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Scenario
      • 7.6.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Scenario
      • 7.6.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Scenario
      • 7.6.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Scenario
      • 7.6.6.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.7. South Korea
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Scenario
      • 7.6.7.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Scenario
      • 7.7.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.7.3. Mexico
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Scenario
      • 7.7.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.7.4. Argentina
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Scenario
      • 7.7.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Scenario
      • 7.8.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Scenario
      • 7.8.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Scenario
      • 7.8.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Scenario
      • 7.8.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Recombinant Protein Therapeutics CDMO Market Share Analysis, 2023
  • 8.3. Major Deals and Strategic Alliances Analysis
    • 8.3.1. Strategy Mapping
    • 8.3.2. Expansion
    • 8.3.3. Partnerships
    • 8.3.4. Acquisitions
  • 8.4. Vendor Landscape
    • 8.4.1. Key company market share analysis, 2023
    • 8.4.2. Richter-Helm BioLogics
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Lonza
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Catalent, Inc
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. FUJIFILM Diosynth Biotechnologies
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. WuXi Biologics
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Curia Global, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Batavia Biosciences B.V.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. HALIX B.V.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. BIOVIAN
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Enzene Biosciences Ltd
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 5 North America Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 6 U.S. Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 8 U.S. Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 9 Canada Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 11 Canada Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Europe Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 14 Europe Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 15 Europe Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 16 UK Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 17 UK Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 18 UK Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 19 Germany Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 20 Germany Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 21 Germany Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 22 France Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 23 France Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 24 France Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Italy Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 26 Italy Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 27 Italy Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Spain Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 29 Spain Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 30 Spain Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 31 Denmark Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 32 Denmark Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 33 Denmark Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 34 Sweden Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 35 Sweden Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 36 Sweden Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 37 Norway Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 38 Norway Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 39 Norway Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Japan Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 45 Japan Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 46 Japan Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 47 China Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 48 China Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 49 China Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 50 India Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 51 India Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 52 India Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 53 Australia Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 54 Australia Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 55 Australia Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 56 Thailand Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 57 Thailand Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 58 Thailand Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 59 South Korea Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 61 South Korea Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Latin America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 64 Latin America Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 65 Brazil Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 66 Brazil Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 67 Brazil Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 68 Mexico Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 69 Mexico Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 70 Mexico Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 71 Argentina Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 72 Argentina Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 73 Argentina Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 74 MEA Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 76 MEA Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 77 MEA Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 78 South Africa Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 79 South Africa Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 80 South Africa Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 84 UAE Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 85 UAE Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 86 UAE Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 87 Kuwait Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Recombinant protein therapeutics CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market outlook, 2022 (USD Billion)
  • Fig. 16 Ancillary market outlook, 2022 (USD Billion)
  • Fig. 17 Recombinant protein therapeutics CDMO market dynamics
  • Fig. 18 Porter's five forces analysis
  • Fig. 19 PESTEL analysis
  • Fig. 20 Recombinant protein therapeutics CDMO market type outlook: Segment dashboard
  • Fig. 21 Recombinant protein therapeutics CDMO market, by type segment: Market share, 2023 & 2030
  • Fig. 22 Growth hormones market, 2018 - 2030 (USD Million)
  • Fig. 23 Interferons market, 2018 - 2030 (USD Million)
  • Fig. 24 Vaccines market, 2018 - 2030 (USD Million)
  • Fig. 25 Immunostimulating agents market, 2018 - 2030 (USD Million)
  • Fig. 26 Others market, 2018 - 2030 (USD Million)
  • Fig. 27 Recombinant protein therapeutics CDMO market source outlook: Segment dashboard
  • Fig. 28 Recombinant protein therapeutics CDMO market, by source segment: Market share, 2023 & 2030
  • Fig. 29 Mammalian systems market, 2018 - 2030 (USD Million)
  • Fig. 30 Microbial systems market, 2018 - 2030 (USD Million)
  • Fig. 31 Others market, 2018 - 2030 (USD Million)
  • Fig. 32 Recombinant protein therapeutics CDMO market indication outlook: Segment dashboard
  • Fig. 33 Recombinant protein therapeutics CDMO market, by indication segment: Market share, 2023 & 2030
  • Fig. 34 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 35 Infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 36 Immunological disorders market, 2018 - 2030 (USD Million)
  • Fig. 37 Metabolic disorders market, 2018 - 2030 (USD Million)
  • Fig. 38 Haematological disorders market, 2018 - 2030 (USD Million)
  • Fig. 39 Others market, 2018 - 2030 (USD Million)
  • Fig. 40 Regional market: Key takeaways
  • Fig. 41 Regional marketplace: Key takeaways
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 North America recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 U.S. recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Canada recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 48 Europe recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 UK recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Germany recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 France recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Italy recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Spain recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Denmark recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Norway recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Japan recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 China recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 India recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Australia recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Clinical trial approval process in South Korea
  • Fig. 76 South Korea recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Thailand recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 79 Latin America recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Brazil recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Mexico recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Argentina recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 86 MEA recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 South Africa recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Saudi Arabia recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Clinical trial authorization process UAE
  • Fig. 93 UAE recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Kuwait recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 96 Market participant categorization
  • Fig. 97 Market participant categorization
  • Fig. 98 Heat map analysis